Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00398411 · OUTCOME

Type of Infection

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells · Source last updated 2015-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)

Analysis population: intention to treat (ITT)

Groups in this outcome

Moxifloxacin

moxifloxacin 400 mg tablets once daily

Placebo

identical appearing placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Moxifloxacin34
Placebo32

Reported measurements

peri-anal abscess
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
mucositis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
pulmonary infiltrate
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo0Not reportedNot reportedNot reportedNot reported
infection at venous catheter
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
herpes infection
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin8Not reportedNot reportedNot reportedNot reported
Placebo8Not reportedNot reportedNot reportedNot reported
candida infection
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo0Not reportedNot reportedNot reportedNot reported
acute respiratory syndrome
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo0Not reportedNot reportedNot reportedNot reported
clostridium difficile infection
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
atypical pneumonia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    peri-anal abscess
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    mucositis
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    pulmonary infiltrate
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    infection at venous catheter
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        8
    title
    herpes infection
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    candida infection
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    acute respiratory syndrome
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    clostridium difficile infection
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    atypical pneumonia
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    2. group Id
      OG001
      value
      32
    units
    Participants
groups
  1. description
    moxifloxacin 400 mg tablets once daily
    id
    OG000
    title
    Moxifloxacin
  2. description
    identical appearing placebo
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
intention to treat (ITT)
reporting Status
POSTED
time Frame
follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)
title
Type of Infection
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice